It starts with a regimen that some patients prefer
In SOLAR, every-2-month CABENUVA was preferred by 9 out of 10 survey respondents vs daily oral therapy with BIKTARVY1

At Month 12 analysis or study withdrawal (secondary endpoint), all CABENUVA-treated patients in SOLAR (mITT-E; n=447) were asked to respond to a question about which regimen they preferred. 22 patients did not respond. Of the 425 survey respondents2:

Patient Ambassador Miranda on long-acting CABENUVA

90%

reported a preference for CABENUVA1,2

  • SOLAR study showed that some patients prefer an every-2-month injectable vs BIKTARVY
  • Patients were asked to compare their experience using CABENUVA versus BIKTARVY, to select the treatment they preferred, and then select from a list of provided statements to support their preference
  • 5% (n=21/425) preferred BIKTARVY and 5% (n=22/425) had no preference

These results are descriptive in nature and should not be used to infer clinical significance.

  • SOLAR Study Design

    SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY1,2

    A large phase 3b, open-label, noninferiority study of virologically suppressed* adults (≥18 years) with HIV-1

    CABENUVA vs BIKTARVY SOLAR study with virologically-suppressed patients
    Primary endpoint, exclusion criteria, and key baseline characteristics for patients in the SOLAR study
    • Efficacy analyses, baseline questionnaire, and preference calculation were based on the mITT-E (N=670) population. After consultation with a blinded external expert, 11 participants at a single study site were excluded from the ITT-E population due to critical findings related to significant and persistent noncompliance to protocol requirements
    • Safety analyses were based on ITT-E (N=681) population
    1. Suppression defined as plasma HIV-1 RNA <50 copies/mL. A single prior INSTI-based regimen was allowed for reasons other than treatment failure.1
    2. 39% (n=173) started with oral lead-in (OLI) and 61% (n=274) of patients in the CABENUVA arm started with injections (SWI) without OLI. OLI regimen consisted of 30-mg cabotegravir and 25-mg rilpivirine once daily given for 1 month; on last day of the OLI period, patients received 2 sets of initiation CABENUVA injections 1 month apart followed by every-2-month injections thereafter.1
    3. Month 12 (OLI and BIKTARVY) and Month 11 (SWI).1
    Primary endpoint, exclusion criteria, and key baseline characteristics for patients in the SOLAR study
Patients prefer CABENUVA survey responses graphic

Why did patients prefer CABENUVA?

The most commonly chosen responses were1*:

85%“I do not have to worry as much about remembering to take HIV medication every day.”

83%“It is more convenient for me to receive injections every 2 months.”

74%“I do not have to carry my HIV medication with me.”

61%“I do not have to think about my HIV status every day.”

59%“I do not have to worry about others seeing or finding my HIV pills.”

Respondents could choose one or more reasons for their preference.1

  1. Patients who preferred CABENUVA were given a list of 11 reasons to choose from; more than one reason could be chosen.

Identifying patients for a long-acting regimen

Patient Amabassador Felix Patient Amabassador Felix

Felix—Patient Ambassador

It was the best change that I have had done so far. CABENUVA fits my lifestyle.

See Felix's story

BMI=body mass index; HBV=hepatitis B virus; INSTI=integrase strand transfer inhibitor; ITT-E=intent-to-treat exposed; mITT-E=modified intent-to-treat exposed.

References:

  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
  2. Data on file. ViiV Healthcare group of companies. Durham, NC.

PMUS-CBRWCNT240041